Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on May 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on April 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
• Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Humana NYSE: HUM on 4/29/2025.

Johnson & Johnson Price Performance

JNJ traded down $1.68 during trading on Friday, reaching $153.98. The stock had a trading volume of 6,519,728 shares, compared to its average volume of 7,900,231. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The firm has a market capitalization of $370.49 billion, a price-to-earnings ratio of 23.15, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The stock has a 50 day moving average of $157.89 and a two-hundred day moving average of $154.29. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Bank of America decreased their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Barclays dropped their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $171.82.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sulzberger Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $453,000. Oregon Pacific Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at $949,000. Horan Securities Inc. lifted its position in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after buying an additional 90 shares in the last quarter. Strategic Financial Concepts LLC boosted its stake in shares of Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock worth $501,000 after buying an additional 1,271 shares during the last quarter. Finally, KPP Advisory Services LLC increased its position in shares of Johnson & Johnson by 4.7% in the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company's stock valued at $1,662,000 after acquiring an additional 515 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.